Autoantibodies: Potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma

Table 5 Diagnostic performance of tumor-associated autoantibody panel in esophagogastric junction adenocarcinoma

Target antigen of auto-anti-bodies	Authors, year	EGJA cases, n	Stage, n					Con-trols, n	Sensiti-vity, all stages/ early stage	Specifi-city, all stages/ early stage	AUC, all stages/ early stage	Method
			0/I	II	III	IV	Unknown
p53, NY-ESO-1, MMP-7, Hsp70, PRDX6 and Bmi-1	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	59.0%/ 50.0%	90.5%/ 90.5%	0.818/ 0.786	ELISA
		70 (Valida-tion)	11	14	30	15	80	80 (Valida-tion)	61.4%/ 56.0%	90.0%/ 90.0%	0.815/ 0.786	ELISA
p53, NY-ESO-1 and Bmi-1	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	53.5%/ 55.6%	90.5%/ 90.5%	0.814/ 0.744	ELISA
		70 (Valida-tion)	11	14	30	15	80	80 (Valida-tion)	60.0%/ 52.0%	93.7%/ 93.7%	0.823/ 0.773	ELISA
p53, Koc, P62, c-Myc, IMP1, Survivin and P16	Zhou et al[41], 2015	75	-	-	-	-	75	140	64.0%/-	87.0%/-	0.73/-	ELISA

EGJA: Esophagogastric junction adenocarcinoma; AUC: Area under the curve; Mmp-7: Matrix metallopeptidase 7; Hsp70: Heat shock protein 70; PRDX 6: Peroxiredoxin 6; Bmi-1: BMI1 proto-oncogene, polycomb ring finger; Koc: Insulin-like growth factor 2 mRNA binding protein 3; C-Myc: MYC proto-oncogene, bHLH transcription factor; IMP1: Insulin-like growth factor 2 mRNA binding protein 1.